Literature DB >> 12353315

N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders.

Shigeharu Tsurumi1, Yuichi Nakamura, Kazuhiro Maki, Mitsuhiro Omine, Kazuhiro Fujita, Takashi Okamura, Yoshiyuki Niho, Sachiko Hashimoto, Keiko Kanno, Kenshi Suzuki, Akira Hangaishi, Seishi Ogawa, Hisamaru Hirai, Kinuko Mitani.   

Abstract

Alterations of the N-ras oncogene and p53 tumor suppressor gene have been demonstrated to play an important role in pathogenesis of hematological malignancies. We simultaneously investigated genetic lesions of both genes in bone marrow cells from 64 Japanese patients with myeloproliferative disorders (MPD), including polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (MF), by direct sequencing analysis. No mutations of the N-ras gene were detected in any cases. Two patients, one with chronic neutrophilic leukemia derived from PV and one with acute mylogenous leukemia derived from ET, exhibited three mutations of the p53 gene. Among them, two were missense mutations in exon 5 or 7 and one was a deletion in exon 5. All samples in chronic phase or from MF were devoid of mutations in both genes. These data suggested that disruptions of both genes are extremely rare in MPD in chronic phase and that loss of functions in the p53 gene could be involved in progression of MPD such as PV and ET. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353315     DOI: 10.1002/ajh.10188

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

Authors:  Min Lu; Xiaoli Wang; Yan Li; Joseph Tripodi; Goar Mosoyan; John Mascarenhas; Marina Kremyanskaya; Vesna Najfeld; Ronald Hoffman
Journal:  Blood       Date:  2012-08-07       Impact factor: 22.113

2.  The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Authors:  Min Lu; Lijuan Xia; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

3.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

4.  Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Annelieke Zeilemaker; Marije Havermans; Claudia Erpelinck; Eric M J Bindels; H Berna Beverloo; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel; Peter J M Valk
Journal:  Blood       Date:  2014-11-07       Impact factor: 22.113

5.  JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines.

Authors:  Wanke Zhao; Yanhong Du; Wanting Tina Ho; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  Exp Hematol Oncol       Date:  2012-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.